The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

Abstract

PPARγ is a member of the PPAR subfamily of nuclear receptors. In this work, the structure of the human PPARγ cDNA and gene was determined, and its promoters and tissue-specific expression were functionally characterized. Similar to the mouse, two PPAR isoforms, PPARγ1 and PPARγ2, were detected in man. The relative expression of human PPARγ was studied by a newly developed and sensitive reverse transcriptase-competitive polymerase chain reaction method, which allowed us to distinguish between PPARγ1 and γ2 mRNA. In all tissues analyzed, PPARγ2 was much less abundant than PPARγ1. Adipose tissue and large intestine have the highest levels of PPARγ mRNA; kidney, liver, and small intestine have intermediate levels; whereas PPARγ is barely detectable in muscle. This high level expression of PPARγ in colon warrants further study in view of the well established role of fatty acid and arachidonic acid derivatives in colonic disease. Similarly as mouse PPARγs, the human PPARγs are activated by thiazolidinediones and prostaglandin J and bind with high affinity to a PPRE. The human PPARγ gene has nine exons and extends over more than 100 kilobases of genomic DNA. Alternate transcription start sites and alternate splicing generate the PPARγ1 and PPARγ2 mRNAs, which differ at their 5′-ends. PPARγ1 is encoded by eight exons, and PPARγ2 is encoded by seven exons. The 5′-untranslated sequence of PPARγ1 is comprised of exons A1 and A2, whereas that of PPARγ2 plus the additional PPARγ2-specific N-terminal amino acids are encoded by exon B, located between exons A2 and A1. The remaining six exons, termed 1 to 6, are common to the PPARγ1 and γ2. Knowledge of the gene structure will allow screening for PPARγ mutations in humans with metabolic disorders, whereas knowledge of its expression pattern and factors regulating its expression could be of major importance in understanding its biology.

Footnotes

  • * This work was supported in part by grants from ARC, INSERM, and Institut Pasteur.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Research associate from the CNRS.

  • §§ Research director from the CNRS and to whom correspondence should be addressed: INSERM U 325, Département d’Athérosclérose, Institut Pasteur, 1 Rue Calmette, F-59019 Lille, France. Fax 33-320-87 73 60; E-mail:Johan.Auwerx{at}pasteur-lille.fr.

  • 1 The abbreviations used are: C/EBP, CCAATT enhancer binding protein; LPL, lipoprotein lipase; kb, kilobase(s); bp, base pair(s); UTR, untranslated region; RACE, rapid amplification of cDNA ends; EMSA, electrophoretic mobility shift assays; ACO, acyl-CoA oxidase; PAC, P1-derived artificial chromosome; PPRE, peroxisome proliferator response element; NIDDM, non-insulin-dependent diabetes mellitus.

    • Received January 27, 1997.
    • Revision received May 2, 1997.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement